Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis.
The V antigen (LcrV) of the plague bacterium Yersinia pestis is a potent protective antigen that is under development as a vaccine component for humans. LcrV is multifunctional. On the bacterial surface it mediates delivery of a set of toxins called Yops into host cells, and as a released protein it can cause production of the immunosuppressive cytokine interleukin-10 (IL-10) and can inhibit chemotaxis of polymorphonuclear neutrophils. It is not known how these mechanisms of LcrV operate, what their relative importance is, when they function during plague, and which are critical to protection by antibody. This study investigated several of these issues. C57BL/6 mice, mice unable to express IL-10, or mice with the macrophage lineage eliminated were treated with a protective anti-LcrV antibody or a nonprotective antibody against YopM and infected intravenously by Y. pestis KIM5 or a strain that lacked the genes encoding all six effector Yops. Viable bacterial numbers were determined at various times. The data indicated that Yops were necessary for Yersinia growth after the bacteria had seeded liver and spleen. Anti-LcrV antibody prevented this growth, even in IL-10-/- mice, demonstrating that one protective mechanism for anti-LcrV antibody is independent of IL-10. Anti-LcrV antibody had no effect on persistence in organs of Y. pestis lacking effector Yops, even though the yersiniae could strongly express LcrV, suggesting that Yops are necessary for building sufficient bacterial numbers to produce enough LcrV for its immunosuppressive effects. In vitro assays showed that anti-LcrV antibody could partially block delivery of Yops and downstream effects of Yops in infected macrophage-like J774A.1 cells. However, cells of the macrophage lineage were found to be dispensable for protection by anti-LcrV antibody in spleen, although they contributed to protection in liver. Taken together, the data support the hypothesis that one protective effect of the antibody is to block delivery of Yops to host cells and prevent early bacterial growth. The findings also identified the macrophage lineage as one host cell type that mediates protection.
Philipovskiy
Alexander V
AV
Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY 40536-0298, USA.
Cowan
Clarissa
C
Wulff-Strobel
Christine R
CR
Burnett
Sandra H
SH
Kerschen
Edward J
EJ
Cohen
Donald A
DA
Kaplan
Alan M
AM
Straley
Susan C
SC
D000818:Animals; D000907:Antibodies, Bacterial / Q000008:administration & dosage* / Q000097:blood / Q000276:immunology*; D000942:Antigens, Bacterial / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000235:genetics / Q000378:metabolism*; D002460:Cell Line; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics; D008264:Macrophages / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D010930:Plague / Q000276:immunology* / Q000382:microbiology; D052899:Pore Forming Cytotoxic Proteins; D011817:Rabbits; D014774:Virulence; D015010:Yersinia pestis / Q000254:growth & development* / Q000276:immunology / Q000472:pathogenicity
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; C043908:LcrV protein, Yersinia; D052899:Pore Forming Cytotoxic Proteins; C060772:yopM protein, Yersinia; D016753:Interleukin-10
Br J Exp Pathol. 1956 Jun;37(3):286-99
13342354
Br J Exp Pathol. 1960 Oct;41:460-71
13694234
J Leukoc Biol. 1997 Apr;61(4):389-96
9103224
Infect Immun. 1995 Aug;63(8):3021-9
7622225
Infect Immun. 1999 May;67(5):2567-74
10225922
Vaccine. 2001 Jul 20;19(30):4175-84
11457543
J Bacteriol. 2002 Aug;184(16):4601-11
12142430
J Cell Biol. 2002 Aug 5;158(3):401-8
12163464
Infect Immun. 2003 Apr;71(4):2234-8
12654847
Immunity. 1999 Oct;11(4):443-51
10549626
Nature. 1957 Jun 15;179(4572):1246-7
13440947
Infect Immun. 1986 Feb;51(2):445-54
3002984
J Immunol. 1959 Oct;83:348-63
13808585
FEMS Immunol Med Microbiol. 1996 Oct;15(4):181-7
8908479
Infect Immun. 2004 Aug;72(8):4589-602
15271919
Infect Immun. 1984 Sep;45(3):649-54
6469351
Infect Immun. 1999 Sep;67(9):4801-13
10456934
Br J Exp Pathol. 1956 Oct;37(5):481-93
13374206
Infect Immun. 1997 Mar;65(3):924-30
9038298
Infect Immun. 1997 Feb;65(2):630-5
9009323
Eur J Immunol. 1995 Jan;25(1):1-5
7843218
Mol Microbiol. 2004 Oct;54(1):75-88
15458406
Mol Microbiol. 2002 Jan;43(2):411-23
11985718
Infect Immun. 1999 Oct;67(10):5395-408
10496922
Immunol Today. 1995 Jan;16(1):21-6
7880385
Science. 1969 Feb 28;163(3870):950-2
5763880
Microbiol Mol Biol Rev. 1998 Dec;62(4):1315-52
9841674
J Bacteriol. 1998 Jan;180(2):350-8
9440524
Microb Pathog. 2002 May;32(5):227-37
12071679
Infect Immun. 2002 Aug;70(8):4165-76
12117925
Infect Immun. 2000 Aug;68(8):4523-30
10899851
Am J Trop Med Hyg. 1997 Apr;56(4):471-3
9158060
Lab Invest. 2004 Oct;84(10):1363-71
15220936
J Infect Dis. 1957 Jan-Feb;100(1):103-7
13416642
J Immunol. 1984 Oct;133(4):2226-30
6381597
Annu Rev Immunol. 2001;19:683-765
11244051
Infect Immun. 1988 Oct;56(10):2749-52
2843471
J Leukoc Biol. 2004 Apr;75(4):612-23
14726498
J Bacteriol. 1988 Jun;170(6):2575-83
2836362
Contrib Microbiol Immunol. 1995;13:325-8
8833864
Microb Pathog. 1998 Mar;24(3):185-96
9514641
Med Microbiol Immunol. 1999 Dec;188(3):151-9
10776846
J Immunol. 2002 Feb 1;168(3):1315-21
11801671
Infect Immun. 1997 Apr;65(4):1196-203
9119451
Infect Immun. 1999 Sep;67(9):4851-61
10456941
Infect Immun. 2003 Jul;71(7):3673-81
12819047
J Infect Dis. 1958 Sep-Oct;103(2):183-7
13588071
J Infect Dis. 1963 Sep-Oct;113:139-43
14064150
J Immunol. 2003 Feb 1;170(3):1383-91
12538698
Contrib Microbiol Immunol. 1987;9:179-85
3665496
Plasmid. 1996 Jan;35(1):1-13
8693022
J Immunol. 2004 Jan 1;172(1):567-76
14688368
Infect Immun. 1984 Mar;43(3):895-900
6365786
J Exp Med. 2002 Oct 21;196(8):1017-24
12391013
Mol Microbiol. 1999 Jun;32(5):961-76
10361299
Clin Infect Dis. 1995 Oct;21 Suppl 2:S178-81
8845449